drugset

drugset / Trial / NCT00328770

De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma

NCT00328770 ↗

Phase 2/3 Completed 70 enrolled University of Alberta

NaSingle-groupOpen-labelTreatment

Summary

This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.

Timeline

Start: 1996-12
Primary completion: 2006-03
Completion: 2006-03

Publications

Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009 Feb;9(2):247-61. doi: 10.1586/14737140.9.2.247.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sirolimus	Small molecule	—	Intravenous

Indications